Feedback?

Based on public information; not affiliated with or endorsed by AstraZeneca.

AstraZeneca: public pathways for academic researchers

Checked 30 Oct 2026.

What AstraZeneca states on its own public pages about process chemistry, crystallization, continuous manufacturing, solid state, impurities, PAT/digital and sustainable processes; named academic programmes; consortium memberships in our directory; calls on this site; and entry points. Every point cites its source. Checked 30 Oct 2026.

Themes: PAT and process modelling (incl. AI/ML-assisted process development) · Flow chemistry · Green and sustainable process

1. What AstraZeneca says publicly

Process chemistry

  • AstraZeneca says finding shorter sequences of reactions to make an API from simple starting materials is "a major focus for our development chemists" (page marked by the site as historic archive material).[2]
  • It describes a photocatalyzed reaction that removed several stages from the manufacturing process for a late-stage cancer medicine (same archived page).[2]

Continuous manufacturing

  • AstraZeneca says flow chemistry, in place of large batches, lets it reduce heating and cooling demands, improve energy efficiency and have greater control when handling reactive steps.[1]

PAT / digital

  • It describes using machine learning to predict and optimise chemical reactions, to reduce waste, energy use and unwanted byproducts (archived page).[2]

Sustainable process

  • AstraZeneca reports optimising route design for a cardiovascular medicine to cut waste and lower CO₂ emissions, and a circular approach to solvent use in its labs (collecting, purifying and reusing solvents).[1]

Not published by the company on the pages we checked: Crystallization, Solid state, Impurities (checked 30 Oct 2026).

2. Named academic programmes

AstraZeneca Open Innovation

  • Through its Open Innovation programme, AstraZeneca says it shares "compounds, tools, technologies and expertise with the scientific community".[5]

CoSolve

  • A "biannual, global Open Innovation programme" posting research challenges within AstraZeneca's R&D focus areas, seeking collaborators from academia, start-ups and early-stage biotechs.[6]
  • The challenges open on 30 Oct 2026 were on nucleotide repeat expansion and a computational model for molecular glue drug discovery; none was on process chemistry or manufacturing.[6]

Externally sponsored scientific research (ESR)

  • Research initiated and managed by an external researcher who takes legal and regulatory responsibility; non-clinical research requests go through the Open Innovation portal.[7]

3. Memberships in our industry directory

4. Open or recurring calls on this site

5. Entry points

What the labels mean
  • Open to applyA funding programme that eligible researchers can apply to, through the route the official page describes.
  • Needs an internal contactA proposal has to start with, or be sponsored by, someone inside the company.
  • Via a consortium or centerEngagement runs through a consortium or centre that names the company; see its card on /industry/.
  • Members onlyOnly paying or member organisations take part.
  • Partnering enquiry (not a funding call)A route to contact the company about a collaboration; it is not a funding programme.
  • Partnering enquiry (not a funding call)CoSolve challenges: Submit a proposal to an open challenge; topics change each round. The CoSolve page does not state funding.[6]
  • Open to applyExternally sponsored research (ESR): External researchers submit proposals; non-clinical requests go via the Open Innovation portal.[7]
  • Open to applyMRC high-throughput screen using AstraZeneca facilities: An MRC-funded call on this site (see the open calls above).[calls]
  • Via a consortium or centerConsortia and centres that name AstraZeneca: See the memberships above; how outsiders take part differs by centre.[memberships]

6. Sources

  1. Sustainable science (astrazeneca.com) · https://www.astrazeneca.com/sustainability/sustainable-science.html · checked 30 Oct 2026
  2. Sustainable drug discovery using Green Chemistry (astrazeneca.com; the site marks this page as historic archive material) · https://www.astrazeneca.com/what-science-can-do/topics/sustainability/sustainable-drug-discovery-using-green-chemistry.html · checked 30 Oct 2026
  3. NIIMBL membership page (combined member list) · https://www.niimbl.org/membership/ · checked 30 Oct 2026
  4. CMAC Medicines Manufacturing Consortium Welcomes Pfizer as Newest Partner (Pfizer press release, 18 Dec 2017) · https://www.pfizer.com/news/press-release/press-release-detail/cmac-medicines-manufacturing-consortium-welcomes-pfizer · checked 30 Oct 2026 (by hand; the site does not allow automated checks)
  5. AstraZeneca Open Innovation · https://openinnovation.astrazeneca.com/ · checked 30 Oct 2026
  6. CoSolve challenges (AstraZeneca Open Innovation) · https://openinnovation.astrazeneca.com/cosolve/cosolve-challenges-open.html · checked 30 Oct 2026
  7. Externally sponsored scientific research (astrazeneca.com) · https://www.astrazeneca.com/partnering/externally-sponsored-scientific-research.html · checked 30 Oct 2026
  8. Enabling Technologies Consortium (ETC): ETC Members · https://etconsortium.org/about-us/ · checked 30 Oct 2026
  9. Medicines Manufacturing Innovation Centre (CPI): Industry partners as announced Nov 2022 (CPI's opening announcement, 30 Nov 2022; no current list is published) · https://www.uk-cpi.com/news/cpi-opens-world-leading-medicines-manufacturing-innovation-centre-in-scotland-to-raise-the-bar-in-pharma-manufacturing · checked 30 Oct 2026

Based on public information; not affiliated with or endorsed by AstraZeneca. Always confirm on the official page.